AR123011A1 - Inhibidores de factores del complemento y usos de los mismos - Google Patents
Inhibidores de factores del complemento y usos de los mismosInfo
- Publication number
- AR123011A1 AR123011A1 ARP210102028A ARP210102028A AR123011A1 AR 123011 A1 AR123011 A1 AR 123011A1 AR P210102028 A ARP210102028 A AR P210102028A AR P210102028 A ARP210102028 A AR P210102028A AR 123011 A1 AR123011 A1 AR 123011A1
- Authority
- AR
- Argentina
- Prior art keywords
- heteroaryl
- alkyl
- aryl
- alkoxy
- heterocyclyl
- Prior art date
Links
- 230000000295 complement effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- -1 amino, hydroxyl Chemical group 0.000 abstract 10
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 7
- 125000000623 heterocyclic group Chemical group 0.000 abstract 7
- 125000003545 alkoxy group Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical group 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 150000002431 hydrogen Chemical group 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000003342 alkenyl group Chemical group 0.000 abstract 5
- 125000004414 alkyl thio group Chemical group 0.000 abstract 5
- 125000000304 alkynyl group Chemical group 0.000 abstract 5
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 5
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 5
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 5
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 abstract 4
- 125000002252 acyl group Chemical group 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 abstract 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 abstract 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 abstract 2
- 125000004442 acylamino group Chemical group 0.000 abstract 2
- 125000003368 amide group Chemical group 0.000 abstract 2
- 229910052796 boron Inorganic materials 0.000 abstract 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 abstract 2
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 2
- 150000002923 oximes Chemical class 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- BUUPQKDIAURBJP-UHFFFAOYSA-N sulfinic acid Chemical compound OS=O BUUPQKDIAURBJP-UHFFFAOYSA-N 0.000 abstract 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 abstract 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000004585 polycyclic heterocycle group Chemical group 0.000 abstract 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
- C07F9/650947—Six-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se divulgan compuestos de fórmula (1) y sales farmacéuticamente aceptables de los mismos. También se divulgan métodos para tratar un trastorno neurodegenerativo, una enfermedad inflamatoria, una enfermedad autoinmunitaria o un trastorno metabólico usando los compuestos divulgados en el presente documento. Reivindicación 1: Un compuesto representado por la fórmula (1) ó (2), o una sal farmacéuticamente aceptable del mismo, en donde: R¹ es hidrógeno, halógeno, amino, hidroxilo, alcoxi o alquiltio; V y W son cada uno, independientemente, CRᵃ o N; cada Rᵃ es independientemente hidrógeno, halógeno, nitro, ciano, amino, hidroxilo, alcoxi, alquiltio o alquilo; X es CRᵇ o N; Rᵇ es hidrógeno, halógeno, nitro, ciano, amino, hidroxilo, alcoxi, alquiltio, alquilo, alquenilo, alquinilo, aralquilo, heteroaralquilo, carbociclilo, heterociclilo, arilo o heteroarilo; cada U es independientemente N o CRᶜ; cada Rᶜ es independientemente hidrógeno, halógeno, alquilo o alcoxi; el anillo Z¹ es un arilo o heteroarilo de cinco o seis miembros; el anillo Z² es un heterociclo de cinco o seis miembros; cada R² es independientemente halógeno, nitro, ciano, amino, acilamino, amido, hidroxilo, alcoxi, alquiltio, acilo, amidino, azido, carbamoílo, carboxilo, carboxiéster, guanidina, haloalquilo, haloalcoxi, heteroalquilo, imino, oxima, fosfonato, óxido de dialquilfosfina, sulfonilo, sulfonamido, sulfonilurea, sulfinilo, ácido sulfínico, ácido sulfónico, tiocianato, tiocarbonilo, alquilo, aralquilo, heteroaralquilo, alquenilo, alquinilo, carbociclilo, heterociclilo, arilo o heteroarilo; o dos R² vecinales, junto con los átomos de carbono intermedios a los que están unidos, se combinan para formar un carbociclo de 5 ó 6 miembros, heterociclo de 5 ó 6 miembros, arilo de 5 ó 6 miembros o heteroarilo de 5 ó 6 miembros; n es 0 o un número entero seleccionado entre 1 - 4, según lo permita la valencia; cada R⁶ es independientemente halógeno, nitro, ciano, amino, acilamino, amido, hidroxilo, oxo, carboxilo, alcoxi, alquiltio, acilo, amidino, azido, carbamoílo, carboxilo, carboxiéster, guanidina, haloalquilo, haloalcoxi, heteroalquilo, imino, oxima, fosfonato, óxido de dialquilfosfina, sulfonilo, sulfonamido, sulfonilurea, sulfinilo, ácido sulfínico, ácido sulfónico, tiocianato, tiocarbonilo, alquilo, alquenilo, alquinilo, aralquilo, heteroaralquilo, carbociclilo, heterociclilo, arilo o heteroarilo; o cualesquiera dos R⁶, junto con el átomo o átomos de carbono intermedios a los que están unidos, se combinan para formar un carbociclo o heterociclo; q es 0 o un número entero seleccionado entre 1 - 4, según lo permita la valencia; R³ es un resto de fórmula (3) ó (4); M es N(R⁸)₃, N(R⁸)₂, OR⁸ o SR⁸; cada R⁸ es independientemente hidrógeno, alquilo, aralquilo, heteroaralquilo, alquenilo, alquinilo, carbociclilo, heterociclilo, arilo o heteroarilo; y R³ᵃ y R³ᵇ son independientemente hidrógeno, alquilo, acilo, alquenilo, alquinilo, aralquilo, heteroaralquilo, carbociclilo, heterociclilo, arilo o heteroarilo; o R³ᵃ y R³ᵇ, junto con el átomo de boro y los dos átomos de oxígeno intermedios que los separan, se combinan para formar heterociclilo monocíclico o policíclico; o R³ᵃ, R³ᵇ y M, junto con el átomo de boro y los átomos de oxígeno intermedios, se combinan para formar un heterociclo policíclico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063054064P | 2020-07-20 | 2020-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123011A1 true AR123011A1 (es) | 2022-10-19 |
Family
ID=79729495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102028A AR123011A1 (es) | 2020-07-20 | 2021-07-19 | Inhibidores de factores del complemento y usos de los mismos |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11814404B2 (es) |
| EP (1) | EP4185592A4 (es) |
| JP (1) | JP7793595B2 (es) |
| KR (1) | KR20230041758A (es) |
| CN (2) | CN116261564A (es) |
| AR (1) | AR123011A1 (es) |
| AU (1) | AU2021311455A1 (es) |
| BR (1) | BR112023001007A2 (es) |
| CA (1) | CA3186022A1 (es) |
| CL (1) | CL2023000191A1 (es) |
| CO (1) | CO2023000683A2 (es) |
| IL (1) | IL299840A (es) |
| MX (1) | MX2023000919A (es) |
| PE (1) | PE20231435A1 (es) |
| PH (1) | PH12023550153A1 (es) |
| TW (1) | TW202216168A (es) |
| UY (1) | UY39331A (es) |
| WO (1) | WO2022020244A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12023550153A1 (en) | 2020-07-20 | 2024-03-18 | Annexon Inc | Inhibitors of complement factors and uses thereof |
| CN118715231A (zh) | 2022-01-14 | 2024-09-27 | 安尼艾克松股份有限公司 | 补体因子抑制剂及其用途 |
| WO2024163405A1 (en) * | 2023-01-30 | 2024-08-08 | 5Metis, Inc. | Boron containing compounds and their uses |
| WO2024254704A1 (en) * | 2023-06-15 | 2024-12-19 | The Governors Of The University Of Alberta | Hemiboronic heterocyclic compounds and uses thereof |
| EP4553080A1 (en) | 2023-11-07 | 2025-05-14 | Ustav Organicke Chemie a Biochemie AV CR, v.v.i. | Nucleoside derivatives as antiviral agents against coronaviruses |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7138298A (en) | 1997-04-24 | 1998-11-13 | Ortho-Mcneil Corporation, Inc. | Substituted imidazoles useful in the treatment of inflammatory diseases |
| JP5120957B2 (ja) * | 2006-01-13 | 2013-01-16 | エルジー・ケム・リミテッド | 発光物質およびこれを用いた有機発光素子 |
| US8221907B2 (en) | 2007-07-07 | 2012-07-17 | Idemitsu Kosan Co., Ltd. | Chrysene derivative and organic electroluminescent device using the same |
| KR101233377B1 (ko) | 2008-12-30 | 2013-02-18 | 제일모직주식회사 | 신규한 유기광전소자용 화합물 및 이를 포함하는 유기광전소자 |
| WO2013049332A1 (en) | 2011-09-29 | 2013-04-04 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
| WO2015003146A1 (en) | 2013-07-03 | 2015-01-08 | Georgetown University | Boronic acid derivatives of resveratrol for activating deacetylase enzymes |
| EA037325B1 (ru) | 2013-07-09 | 2021-03-12 | Аннексон, Инк. | Антитела против фактора комплемента c1q и их применения |
| TWI532741B (zh) | 2013-09-04 | 2016-05-11 | 喜星素材股份有限公司 | 含吡唑之多環化合物及使用其之有機發光裝置 |
| KR101635154B1 (ko) * | 2014-08-28 | 2016-06-30 | (주)더블유에스 | 피리딜기가 결합된 트리아진 유도체 및 이를 포함한 유기 전계발광 소자 |
| KR102233296B1 (ko) * | 2014-11-18 | 2021-03-29 | 덕산네오룩스 주식회사 | 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치 |
| AR103397A1 (es) * | 2015-01-13 | 2017-05-10 | Syngenta Participations Ag | Oxoborazoles microbicidas |
| CN107530356A (zh) * | 2015-03-13 | 2018-01-02 | 雷斯韦洛吉克斯公司 | 用于治疗补体相关疾病之组合物及治疗方法 |
| KR101981245B1 (ko) | 2015-10-27 | 2019-05-22 | 주식회사 엘지화학 | 고리 화합물 및 이를 포함하는 유기 발광 소자 |
| KR101806464B1 (ko) | 2015-11-19 | 2017-12-07 | (주)랩토 | 피리딜기가 결합된 피리미딘 유도체 및 이를 이용한 유기 전계 발광 소자 |
| KR102496411B1 (ko) | 2016-01-06 | 2023-02-06 | 덕산네오룩스 주식회사 | 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치 |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| KR102238925B1 (ko) * | 2018-06-11 | 2021-04-12 | 주식회사 엘지화학 | 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자 |
| WO2020032428A1 (ko) * | 2018-08-09 | 2020-02-13 | 덕산네오룩스 주식회사 | 유기전기 소자용 화합물을 포함하는 유기전기소자 및 그 전자 장치 |
| CN109574917B (zh) | 2018-12-03 | 2020-12-08 | 武汉尚赛光电科技有限公司 | 一种芴酮衍生物及其制备和应用 |
| CN109574910B (zh) * | 2018-12-19 | 2021-07-02 | 山西大学 | 一种咔唑衍生物mcab及其制备方法和应用 |
| CN111087387B (zh) * | 2019-12-26 | 2022-04-29 | 厦门天马微电子有限公司 | 一种有机化合物、显示面板及显示装置 |
| CN111423390A (zh) | 2020-03-30 | 2020-07-17 | 北京燕化集联光电技术有限公司 | 一种新型结构化合物及其应用 |
| CN111662309B (zh) | 2020-07-10 | 2021-11-09 | 北京燕化集联光电技术有限公司 | 一种多杂环结构化合物及其应用 |
| PH12023550153A1 (en) | 2020-07-20 | 2024-03-18 | Annexon Inc | Inhibitors of complement factors and uses thereof |
| CN113045585A (zh) | 2021-03-16 | 2021-06-29 | 吉林奥来德光电材料股份有限公司 | 一种有机稠环化合物及其制备方法和应用 |
| CN113831332B (zh) | 2021-10-29 | 2024-06-18 | 长春海谱润斯科技股份有限公司 | 一种含氮杂环衍生物及其在有机电致发光器件中的应用 |
| CN118715231A (zh) | 2022-01-14 | 2024-09-27 | 安尼艾克松股份有限公司 | 补体因子抑制剂及其用途 |
-
2021
- 2021-07-19 PH PH1/2023/550153A patent/PH12023550153A1/en unknown
- 2021-07-19 KR KR1020237005805A patent/KR20230041758A/ko active Pending
- 2021-07-19 EP EP21845924.6A patent/EP4185592A4/en active Pending
- 2021-07-19 US US17/379,334 patent/US11814404B2/en active Active
- 2021-07-19 PE PE2023000109A patent/PE20231435A1/es unknown
- 2021-07-19 CN CN202180059041.6A patent/CN116261564A/zh active Pending
- 2021-07-19 IL IL299840A patent/IL299840A/en unknown
- 2021-07-19 MX MX2023000919A patent/MX2023000919A/es unknown
- 2021-07-19 WO PCT/US2021/042198 patent/WO2022020244A1/en not_active Ceased
- 2021-07-19 CA CA3186022A patent/CA3186022A1/en active Pending
- 2021-07-19 AR ARP210102028A patent/AR123011A1/es unknown
- 2021-07-19 JP JP2023503413A patent/JP7793595B2/ja active Active
- 2021-07-19 AU AU2021311455A patent/AU2021311455A1/en active Pending
- 2021-07-19 CN CN202310870524.5A patent/CN116947903A/zh active Pending
- 2021-07-19 BR BR112023001007A patent/BR112023001007A2/pt unknown
- 2021-07-20 UY UY0001039331A patent/UY39331A/es unknown
- 2021-07-20 TW TW110126637A patent/TW202216168A/zh unknown
-
2023
- 2023-01-19 CL CL2023000191A patent/CL2023000191A1/es unknown
- 2023-01-20 CO CONC2023/0000683A patent/CO2023000683A2/es unknown
- 2023-10-04 US US18/376,526 patent/US12509474B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023000919A (es) | 2023-04-19 |
| TW202216168A (zh) | 2022-05-01 |
| AU2021311455A1 (en) | 2023-02-16 |
| EP4185592A4 (en) | 2024-08-21 |
| PH12023550153A1 (en) | 2024-03-18 |
| CN116261564A (zh) | 2023-06-13 |
| CO2023000683A2 (es) | 2023-01-26 |
| BR112023001007A2 (pt) | 2023-03-28 |
| PE20231435A1 (es) | 2023-09-14 |
| US20220048930A1 (en) | 2022-02-17 |
| JP7793595B2 (ja) | 2026-01-05 |
| UY39331A (es) | 2022-02-25 |
| IL299840A (en) | 2023-03-01 |
| JP2023534974A (ja) | 2023-08-15 |
| US20240109920A1 (en) | 2024-04-04 |
| CN116947903A (zh) | 2023-10-27 |
| CL2023000191A1 (es) | 2023-09-08 |
| CA3186022A1 (en) | 2022-01-27 |
| US12509474B2 (en) | 2025-12-30 |
| WO2022020244A1 (en) | 2022-01-27 |
| US11814404B2 (en) | 2023-11-14 |
| KR20230041758A (ko) | 2023-03-24 |
| EP4185592A1 (en) | 2023-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR123011A1 (es) | Inhibidores de factores del complemento y usos de los mismos | |
| AR118856A2 (es) | Compuestos terapéuticos | |
| AR091981A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| AR114254A1 (es) | Moduladores del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso de preparación de los moduladores | |
| AR098414A1 (es) | PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e | |
| AR108130A1 (es) | Derivados de pirazolopirimidina | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR110346A1 (es) | Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador | |
| RU2014129742A (ru) | Производные бензолсульфонамида в качестве модуляторов rorc | |
| AR095430A1 (es) | Compuestos de pirimidina y piridina y su uso como inhibidores de la actividad de fgfr | |
| AR090945A1 (es) | Moduladores de la via del complemento y usos de los mismos | |
| AR087757A1 (es) | Inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7, sus composiciones farmaceuticas y sus aplicaciones terapeuticas | |
| AR096620A1 (es) | Derivado de aminotriazina y composición farmacéutica que lo comprende | |
| AR105643A1 (es) | COMPUESTOS ANTIVIRALES DE FOSFODIAMIDA DE ÉSTER DE b-AMINOÁCIDO | |
| AR087543A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
| AR093143A1 (es) | Compuestos de 2-aminopiridina | |
| AR086411A1 (es) | Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria | |
| AR110238A1 (es) | Derivado de pirido[3,4-d]pirimidina y su sal farmacéuticamente aceptable | |
| AR039401A1 (es) | Un compuesto antagonista de integrinas alfa 4 y un procedimiento para preparar el mismo | |
| AR124303A1 (es) | Inhibidores de irak4 | |
| AR091534A1 (es) | Derivados de sulfonamida y metodos de uso de los mismos para mejorar la farmacocinetica de un farmaco | |
| AR088639A1 (es) | Composicion farmaceutica oftalmica, compuestos antimicrobianos a base de carbolina | |
| PE20240213A1 (es) | Compuestos como moduladores de bis-fosfoglicerato mutasa para el tratamiento de la anemia de celulas falciforme | |
| RU2015121347A (ru) | Производные, содержащие циклическую сульфонамидную группу, в качестве ингибиторов сигнального пути hedgenog | |
| AR130961A1 (es) | Compuestos y su uso para el tratamiento de hemoglobinopatías |